Social network
Our responsibility

Tools content (print, share, increase/decrease text size):

 

Stopping tuberculosis

.Tuberculosis (TB) is one of the deadliest infectious diseases in the world. In 2014, there were 9.6 million new cases causing 1.5 million deaths worldwide, most of them occurring in developing countries.

In about 9 out of 10 infected people, tuberculosis will remain latent1. However, the risk of developing an active form of TB is much higher for individuals whose immune system is compromised (due to HIV, treatment with immunosuppressant, malnutrition, diabetes, etc.).

 

Simplifying treatment

When taken properly, the treatment for active tuberculosis is highly effective. However, it is long and complex. Poor compliance not only puts the patient at risk of treatment failure, it also promotes the development of antibiotic-resistant bacteria and the spread of the disease.

Sanofi has collaborated with the Centers for Disease Control and Prevention (CDC) of Atlanta (USA) and their international network to simplify the treatment of latent tuberculosis thus reducing a daily dosing regimen for 6-9 months to a weekly dosing regimen for only 3 months. This new regimen (rifapentine/isoniazid) was approved by the FDA and recommended by the WHO Guidelines for the management of latent tuberculosis infection in December 2014. The research with the CDC is also moving towards a reduction in the duration of treatment of non-resistant active TB (2 months reduction).

 

Fighting resistant forms of TB

Sanofi collaborates with the TB Alliance, a non-profit organization, to identify new medicines that are effective against all forms of tuberculosis, including multi-resistant forms.

 

For more information:

 

 

References :

  1. WHO Media Center, Tuberculosis, Fact sheet No. 104, March 2016
 
 

© Sanofi 2004-2017 - All rights reserved - Update: November 28, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)